DEP® posters showcased at AACR 2020
Four DEP® products were featured in five poster presentations at the 2020 Annual American Association for Cancer Research Annual Meeting in June 2020. These include three posters featuring AstraZeneca’s first DEP® oncology product AZD0466, and two posters which showcase Starpharma’s three phase 2 products, DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan.
1718 / 4 - Design and optimization of a dendrimer-conjugated dual Bcl-2/Bcl-xL inhibitor, AZD0466, with improved therapeutic index
56 / 2 - AZD0466, a nanomedicine of a potent dual Bcl-2/Bcl-xL inhibitor, exhibits anti-tumor activity in a range of hematological and solid tumor models
3075 / 9 - Anti-leukemic activity of BCL-2/BCL-XL dual inhibitor - AZD0466 in T-acute lymphoblastic leukemia preclinical models (external link)
These posters highlight the significant improvement in therapeutic index delivered to AZD0466 through the application of the DEP® technology, enabling its progression into the clinic. The posters also highlight the potent and broad ranging anti-cancer activity of AZD0466 which results from the dual Bcl2 and Bcl/xL activity. AZD0466 demonstrated superior anti-cancer activity in a wide range of preclinical tumour models including Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin’s Lymphoma and Small Cell Lung Cancer (SCLC).
DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan
1715 / 1 - Anti-cancer activity of a SN-38 nanoparticle, DEP® irinotecan, in human colon and pancreatic cancer xenograft models
1716 / 2 - Anticancer activity of the taxane nanoparticles, DEP® docetaxel and DEP® cabazitaxel
The preclinical data presented in the two posters above comprise a series of xenograft studies showing enhanced efficacy of DEP® candidates/products used as a monotherapy or in combination with standard of care therapies.
If you experience any difficulty downloading posters, please email email@example.com.